Prognostic value and clinicopathological significance of epithelial cadherin expression in non-small cell lung cancer

被引:3
作者
Qiu, Zhi-Xin [1 ]
Zhao, Shuang [1 ]
Li, Lei [1 ]
Li, Wei-Min [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Resp Med, Chengdu 610041, Peoples R China
关键词
E-cadherin; meta-analysis; metastasis; non-small cell lung cancer (NSCLC); overall survival (OS); ALPHA-CATENIN EXPRESSION; BETA-CATENIN; IMMUNOHISTOCHEMICAL ANALYSIS; MOLECULAR MARKERS; DOWN-REGULATION; GASTRIC-CANCER; GAMMA-CATENIN; STAGE; GROWTH; PROGRESSION;
D O I
10.1111/1759-7714.12227
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundEpithelial cadherin (E-cadherin), a calcium-dependent cell-cell adhesion molecule, as an important adhesion and signaling pathway mediator plays key roles in the maintenance of tissue integrity. However, the available results of E-cadherin expression and its prognostic value on non-small cell lung cancer (NSCLC) remain controversial. Therefore, a meta-analysis of published studies investigating the prognostic value of E-cadherin expression and its association with clinicopathological characteristics with NSCLC was performed. MethodsA literature search via PubMed, EMBASE, and MEDLINE (Ovid) databases was conducted. Data from eligible studies were extracted. Statistical analysis was performed using STATA 12.0. ResultsA total of 2412 patients from 15 studies were included in the meta-analysis. The results showed that the pooled hazard ratio (HR) for overall survival was 0.55 (95% confidence interval [CI]: 0.44-0.69) by univariate analysis and 0.68 (95% CI: 0.43-1.08) by multivariate analysis. In addition, the results showed a significant association between E-cadherin expression and the presence of lymph node metastasis (odds ratio = 0.37, 95% CI=0.05-0.69, P = 0.001). ConclusionOur study showed that positive expression of E-cadherin was associated with a favorable prognosis in patients with NSCLC, and might act as an inhibition factor of metastasis. However, adequately designed prospective studies are required to confirm this finding.
引用
收藏
页码:589 / 596
页数:8
相关论文
共 49 条
[1]   The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer [J].
Al-Saad, S. ;
Al-Shibli, K. ;
Donnem, T. ;
Persson, M. ;
Bremnes, R. M. ;
Busund, L-T .
BRITISH JOURNAL OF CANCER, 2008, 99 (09) :1476-1483
[2]   Expression of E-cadherin, α-catenin, β-catenin, and CD44 (Standard and variant isoforms) in human cholangiocarcinoma:: An immunohistochemical study [J].
Ashida, K ;
Terada, T ;
Kitamura, Y ;
Kaibara, N .
HEPATOLOGY, 1998, 27 (04) :974-982
[3]  
Bailey T, 1998, AM J PATHOL, V152, P135
[4]  
Chen Xiaofeng, 2002, Zhongguo Fei Ai Za Zhi, V5, P260, DOI 10.3779/j.issn.1009-3419.2002.04.06
[5]   A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers [J].
D'Amico, TA ;
Massey, M ;
Herndon, JE ;
Moore, MB ;
Harpole, DH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (04) :736-742
[6]   Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry [J].
Deeb, G ;
Wang, JM ;
Ramnath, N ;
Slocum, HK ;
Wiseman, S ;
Beck, A ;
Tan, DF .
MODERN PATHOLOGY, 2004, 17 (04) :430-439
[7]   Molecular markers for predicting prostate cancer stage and survival [J].
Dunsmuir, WD ;
Gillett, CE ;
Meyer, LC ;
Young, MP ;
Corbishley, C ;
Eeles, RA ;
Kirby, RS .
BJU INTERNATIONAL, 2000, 86 (07) :869-878
[8]  
Fadare O, 2009, INT J CLIN EXP PATHO, V2, P411
[9]   FoxQ1 Overexpression Influences Poor Prognosis in Non-Small Cell Lung Cancer, Associates with the Phenomenon of EMT [J].
Feng, Jian ;
Zhang, Xuesong ;
Zhu, Huijun ;
Wang, Xudong ;
Ni, Songshi ;
Huang, Jianfei .
PLOS ONE, 2012, 7 (06)
[10]   Circulating MicroRNAs: Possible Prediction Biomarkers for Personalized Therapy of Non-Small-Cell Lung Carcinoma [J].
Gao, Wen ;
Liu, Lingxiang ;
Lu, Xiao ;
Shu, Yongqian .
CLINICAL LUNG CANCER, 2011, 12 (01) :14-17